Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management

[1]  Soo-Mi Park,et al.  Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review , 2017, The Journal of clinical endocrinology and metabolism.

[2]  Jenny Welander,et al.  Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas , 2017, Nature Reviews Endocrinology.

[3]  A. Hartmann,et al.  Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer , 2016, Nature Communications.

[4]  W. Chung,et al.  Von Hippel-Lindau Disease: Genetics and Role of Genetic Counseling in a Multiple Neoplasia Syndrome. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Vignoli,et al.  Do patients with tuberous sclerosis complex have an increased risk for malignancies? , 2016, American journal of medical genetics. Part A.

[6]  H. Moch,et al.  Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. , 2016, European urology.

[7]  B. Dickson,et al.  Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association , 2015, Virchows Archiv.

[8]  C. Stratakis,et al.  Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. , 2015, The Journal of clinical endocrinology and metabolism.

[9]  E. Maher,et al.  VHL, the story of a tumour suppressor gene , 2014, Nature Reviews Cancer.

[10]  James B. Mitchell,et al.  Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. , 2014, Cancer cell.

[11]  J. McKenney,et al.  Succinate Dehydrogenase (SDH)-deficient Renal Carcinoma: A Morphologically Distinct Entity , 2014, The American journal of surgical pathology.

[12]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment , 2014, Familial Cancer.

[13]  W. Linehan,et al.  Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment , 2014, Familial Cancer.

[14]  M. Simpson,et al.  Germline FH mutations presenting with pheochromocytoma. , 2014, The Journal of clinical endocrinology and metabolism.

[15]  M. Berger,et al.  Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome–associated Renal Cancer: Recognition of the Syndrome by Pathologic Features and the Utility of Detecting Aberrant Succination by Immunohistochemistry , 2014, The American journal of surgical pathology.

[16]  G. Bratslavsky,et al.  Hereditary renal cell carcinoma: genetics, clinical features, and surgical considerations , 2014, World Journal of Urology.

[17]  W. Linehan,et al.  Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  W. Linehan,et al.  Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. , 2013, The Journal of urology.

[19]  S. Pautler,et al.  Canadian guideline on genetic screening for hereditary renal cell cancers. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[20]  G. Gyapay,et al.  Germline BAP1 mutations predispose to renal cell carcinomas. , 2013, American journal of human genetics.

[21]  N. Grishin,et al.  A Novel Germline Mutation in BAP1 Predisposes to Familial Clear-Cell Renal Cell Carcinoma , 2013, Molecular Cancer Research.

[22]  B. K. Park,et al.  Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease: indications, techniques, complications, and outcomes , 2013, Acta radiologica.

[23]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  I. Tomlinson,et al.  Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression , 2012, Nature Genetics.

[25]  Gabriela Kalna,et al.  Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase , 2011, Nature.

[26]  J. Becker,et al.  Germline mutations in BAP1 predispose to melanocytic tumors , 2011, Nature Genetics.

[27]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[28]  S. Richard,et al.  von Hippel–Lindau disease: A clinical and scientific review , 2011, European Journal of Human Genetics.

[29]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[30]  E. Maher,et al.  Population‐based survey of cancer risks in chromosome 3 translocation carriers , 2010, Genes, chromosomes & cancer.

[31]  S. Richard,et al.  Birt-Hogg-Dubé syndrome: diagnosis and management. , 2009, The Lancet. Oncology.

[32]  W. Linehan,et al.  Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2 , 2009, Proceedings of the National Academy of Sciences.

[33]  E. Henske,et al.  The role of the Birt–Hogg–Dubé protein in mTOR activation and renal tumorigenesis , 2009, Oncogene.

[34]  S. Richard,et al.  Familial Non-VHL Clear Cell (Conventional) Renal Cell Carcinoma: Clinical Features, Segregation Analysis, and Mutation Analysis of FLCN , 2008, Clinical Cancer Research.

[35]  C. Ricketts,et al.  Germline SDHB mutations and familial renal cell carcinoma. , 2008, Journal of the National Cancer Institute.

[36]  Peter L Choyke,et al.  The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. , 2005, The Journal of urology.

[37]  E. Maher,et al.  Genotype–phenotype correlations in von Hippel‐Lindau disease , 2004, Human mutation.

[38]  P. Choyke,et al.  Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. , 2003, American journal of human genetics.

[39]  W. Linehan,et al.  Renal Tumors in the Birt-Hogg-Dubé Syndrome , 2002, The American journal of surgical pathology.

[40]  Maria Merino,et al.  Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. , 2002, Cancer cell.

[41]  Charles C Wykoff,et al.  HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. , 2002, Cancer cell.

[42]  A. Paetau,et al.  Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.

[43]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[44]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[45]  C. Larsson,et al.  A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. , 2000, The Journal of clinical endocrinology and metabolism.

[46]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[47]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[48]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[49]  N. Morton,et al.  Von Hippel-Lindau disease: a genetic study. , 1991, Journal of medical genetics.

[50]  M. Ferguson-Smith,et al.  Clinical features and natural history of von Hippel-Lindau disease. , 1990, The Quarterly journal of medicine.

[51]  M. Ferguson-Smith,et al.  Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. , 1990, Journal of medical genetics.

[52]  S. West.  Recurrent Pneumothorax , 1889 .

[53]  E. Maher,et al.  Diagnosis and Management of Hereditary Renal Cell Cancer. , 2016, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.